Cargando…
Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-bilnd- placebo-controlled exploratory phase 2 trial. Methods: One-hundred forty patients with DLB,...
Autores principales: | Mori, Etsuro, Ikeda, Manabu, Kosaka, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504981/ https://www.ncbi.nlm.nih.gov/pubmed/22829268 http://dx.doi.org/10.1002/ana.23557 |
Ejemplares similares
-
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
por: Ikeda, Manabu, et al.
Publicado: (2015) -
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
por: Mori, Etsuro, et al.
Publicado: (2015) -
Aphasic mild cognitive impairment in prodromal dementia with Lewy bodies
por: Watanabe, Hiroyuki, et al.
Publicado: (2023) -
Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014) -
Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report
por: Watanabe, Hiroyuki, et al.
Publicado: (2020)